Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Diabetes

Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN

June 18, 2013

Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site

Business briefs: Novo Nordisk, Eli Lilly, Merck

June 17, 2013

Analysts say Novo Nordisk's Victoza should brace for Eli Lilly competition; Lilly halts an Alzheimer's study; and Japan reverses its HPV vaccination stance.

Business briefs: Boehringer Ingelheim, Teva, Medicare

June 12, 2013

Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients

Weight-loss category expands by one

Deborah Weinstein June 11, 2013

Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.

Business briefs: AbbVie, Teva, HIV, Diabetes, iPhone

May 30, 2013

AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters.

Business briefs: AbbVie, AstraZeneca, Valeant, Merck, Novo Nordisk

May 28, 2013

AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight loss results.

Business briefs: Actavis, Bayer, Oramed, Elan

May 20, 2013

Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M

Business briefs: Pfizer, BMS, CMS, Sanofi

May 16, 2013

Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor.

Business briefs: Baxter; Eli Lilly; CDHPs and Statins

May 07, 2013

Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.

BI, Lilly go simple in new SGLT med-ed effort

Marc Iskowitz May 07, 2013

Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.

Business briefs: Sanofi, Allergan, Otsuka, Genmab, NIH, Novartis, DOJ

May 02, 2013

Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling.

Merck throws more staff behind Januvia; overall sales slid for quarter

Deborah Weinstein May 01, 2013

Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise.

Breakup, Xeljanz plans dominate Pfizer earnings call

Deborah Weinstein April 30, 2013

Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe.

Patent losses stalk BMS, AZ quarterly results

Deborah Weinstein April 25, 2013

Brass-plated brands Plavix and Seroquel continue to lose luster on the two drug makers' balance sheets.

Higher prices keep Lilly's quarter flat; Cymbalta DTC pull-back planned

Deborah Weinstein April 24, 2013

Lilly said sales-force downsizing was the right move considering the current portfolio mix and generics shadow. Management also teased some vague pipeline details.

Studies show cost doesn't drive everything

Deborah Weinstein April 22, 2013

Two studies show that it's not enough to focus on cost to alter healthcare.

Abbott closes Q1 with sales boost

Deborah Weinstein April 17, 2013

The company expects emerging markets to rise in importance and says it's scoping out possible device acquisitions.

Charlie Kimball talks Novo Racing with insulin

Deborah Weinstein April 16, 2013

IndyCar's first licensed driver heads up a diabetes awareness campaign that focuses on community—both online and in real life.

Business briefs: GlaxoSmithKline, Adverse Event reporting, Elan

April 15, 2013

GSK's Avandia woes continue, study finds a new way to identify adverse events, and Royalty ups its bid for Elan.

Lilly to boost diabetes sales force amid layoffs in other categories

Deborah Weinstein April 12, 2013

Expiring patents force a sales staff slim-down, but the drug maker emphasizes it is not eliminating its sales force.

Oncology lifts Roche's Q1, Lucentis finds new fans

Deborah Weinstein April 11, 2013

Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.

Business briefs: Walgreens; Pfizer; Roche

April 04, 2013

Walgreens retail clinics expand diagnostic services, Pfizer says OTC is staying put, Roche-BMS melanoma drug mix runs into PHI troubles.

Success in emerging markets hinges on broad network

Deborah Weinstein April 03, 2013

Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.

Business briefs: AstraZeneca, Everyday Health, J&J

April 02, 2013

AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales

J&J's Invokana clears FDA

Matthew Arnold March 29, 2013

The FDA has approved Janssen's Invokana (canagliflozin) for type 2 diabetes, giving J&J a first-to-market advantage in the SGLT-2 class.

Why SGLT-2s may put some spring into pharma spending

Jerry Maynor March 28, 2013

Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.

Business briefs: United Concordia, FDA

March 27, 2013

United Concordia finds a way to slash healthcare costs for $4,000 a year, and FDA goes on tour to promote tighter compounding oversight

Business Briefs: Roche, Sanofi, J&J

March 26, 2013

NICE pans Avastin for ovarian cancer (again), Sanofi wants data innovators

Business briefs: HRT, HPV, Novo Nordisk

March 18, 2013

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results

Vivus launches Qsymia weight-loss app

Deborah Weinstein March 13, 2013

The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.

Web Exclusive

What NOT to say to an MS Patient

Dorothy Wetzel June 07, 2013

It is often hard to find the right words when talking to a patient, friend or family member with MS. Even with training and awareness of the disease, we often blurt out something we think is innocuous only to find out later that we have deeply offended. The Health Activists that Extrovertic spoke to had some suggestions for having positive conversations with someone with MS.

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma.

Slideshows

Peter Frishauf, founder of Medscape, delivers his acceptance speech.

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner

Most Popular
Most Emailed
Most Recent